Physician profile
Noah Britton
NPI 1649673625
$3,091.89
in general payments reported to CMS, 2019-2025
21 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $807 · 2022: $891 · 2023: $508 · 2024: $742 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322 · Education: $71.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.71 |
| Education | $71.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $574.01 | 2021-2023 | Veltassa, Korsuva |
| Amgen INC. | $529.58 | 2021-2024 | Tavneos, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $381.96 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $254.30 | 2023-2024 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $186.86 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $159.29 | 2021-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $142.49 | 2021-2023 | Acthar |
| Akebia Therapeutics INC | $141.29 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $87.02 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $77.99 | 2022-2024 | Farxiga, Lokelma |
| Ardelyx, INC. | $75.07 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $74.00 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $72.56 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $71.66 | 2023 | Rayaldee |
| Daiichi Sankyo INC. | $70.68 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $65.96 | 2022-2023 | Velphoro, Korsuva |
| Calliditas Therapeutics US INC. | $40.97 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.56 | 2024 | Jardiance |
| Novo Nordisk INC | $20.89 | 2025 | |
| Genzyme Corporation | $20.28 | 2021 | |
| Lilly USA, LLC | $18.47 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Britton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.